Recent evidence suggests that MDMA-assisted Psychotherapy for the treatment of PTSD might help treatment-resistant patients. Treatment-resistant post-traumatic stress disorder patients do not have many therapeutic options since the currently used medications are of limited help. MDMA is an empathogen-entactogen drug that affects various processes of fear extinction, emotional processing, and memory reconsolidation. In the first phase-3 RCT by Mitchell et al. the MDMA-assisted therapy group showed a greater CAPS-5 score reduction (-24.4) compared to the placebo group (-13.9) after three sessions. MDMA was found to be safe, well-tolerated and with high efficacy in the treatment of severe PTSD, as well as the dissociative type of PTSD, compared to placebo. At the end point of the primary phase-3 study 67% of the participants in the MDMA group compared to 32% of the participants in the placebo group no longer met the diagnostic criteria for PTSD. MDMA-Assisted Psychotherapy is a potential candidate for being a first-line treatment for PTSD, upon approval from the FDA, with greater efficacy, length of remission, safety, and side effect profile compared to placebo.